Innate Pharma Sa Class A · EURONEXT:IPH
Innate Pharma Sa Class A — Investor Presentation (June 2018)
44 slides from Innate Pharma Sa Class A's investor presentation, June 2018
Slide 1: Company Presentation
“P, & innate pharma COMPANY PRESENTATION
Slide 2: Forward Looking Statement
FORWARD LOOKING STATEMENT This document has been prepared by Innate Pharma S.A. (the The information contained herein has not been independently “Company”) solely for the purposes of a presentation to verified. No representation, warranty or undertaking, express or investors concerning the Company.
Slide 3: Innate Pharma – At a Glance
INNATE PHARMA – AT A GLANCE • Headquarters in Marseille • >180 employees • 4 products at clinical stage, including 2 proprietary ones • Major collaborations with big pharmas • Broad R&D pipeline • €153.8 million in Cash* • Listed on Euronext Paris As of March 31, 2018 * cash, cash equivalents as wel
Slide 4: Innate Pharma – Leadership Team
INNATE PHARMA – LEADERSHIP TEAM Mondher Pierre Jérôme MAHJOUBI, MD, DODION, MD, MBA, TIOLLIER, PhD, Chief Executive Officer Chief Medical Officer Chief Development Officer AstraZeneca, ARIAD, Pfizer, Genentech, Roche Novartis, Aventis Pasteur Merieux Sangstat Yannis Laure-Hélène Eric MOREL, PhD, MER
Slide 5: Immunotherapy: Changing the Standard of Care in Oncology
IMMUNOTHERAPY CHANGING THE STANDARD OF CARE IN ONCOLOGY Today • Approved in different types of cancer • Deep and durable responses only for a minority of patients Tomorrow Improve patient responses: • Biomarkers • Combination strategies • Override immunosuppression in the tumor microenvironment Shar
Slide 6: Innate Pharma – Strategy
INNATE PHARMA – STRATEGY SCIENCE DRIVEN ORGANIZATION AND PATIENT CENTRIC COMPANY Create diverse portfolio of first or best-in-class IO agents Strategic Partner with leading IO companies to unlock the value of assets Priorities with substantial market potential Retain more value in house and move tow
Slide 7: Innate Pharma – Approach
INNATE PHARMA – APPROACH SCIENTIFIC EXCELLENCE AROUND 3 KEY PILLARS 1 2 3 Immune Tumor Tumor checkpoints antigen microenvironment (CP) (TAg) (TME) Page 7
Slide 8: Innate Pharma – Pipeline: Targeting Different Status of Immune Response
INNATE PHARMA – PIPELINE TARGETING DIFFERENT STATUS OF THE IMMUNE RESPONSE No effective Anti-tumor immunity Sub-optimal or exhausted anti-tumor immunity suppressed by TME anti-tumor immunity Noninflamed Inflamed NK Bispecific IPH5401 Monalizumab Engagers Anti-C5aR Anti-NKG2A Antibody Drug IPH53 IPH4
Slide 9: Innate Pharma – Pipeline
INNATE PHARMA – PIPELINE FOR FIRST-IN-CLASS IMMUNO-ONCOLOGY (IO) ASSETS Drug Signal Preclinical Dose finding Pivotal Discovery detection IPH52 IPH5401 Monalizumab Anti-Siglec-9 Anti-CD39 Anti-C5aR Anti-NKG2A IPH53 IPH4102 SAN-NKCE-2 Anti-CD73 Anti-KIR3DL2 Other undisclosed IPH4301 targets Anti-MICA/
Slide 10: Innate Pharma – Short Term Value Creation Steps
INNATE PHARMA – SHORT TERM VALUE CREATION STEPS • Read-out of current clinical programs > Monalizumab w/ cetuximab in advanced SCCHN > Monalizumab w/ durvalumab in solid tumors > Cohort expansion data for IPH4102 KEY • Preparing next stages of clinical studies CATALYSTS > IPH4102: lifting the full p
Slide 11: Innate Pharma – Long Term Catalysts
INNATE PHARMA – LONG TERM CATALYSTS IPH52 IPH52 combo IPH52 potential Ph1 Ph1/2 pivotal program* FIRST PATIENT IN IPH5401 + Durva IPH5401 + PD1/L1 IPH43 IPH5401 potential IPH43 IPH43 potential Ph1/2 Ph2-3rd indication Ph1/2 pivotal program* Ph2/3 pivotal program* IPH4102 IPH4102 IPH4102 Pivotal-SS P
Slide 12: Monalizumab
MONALIZUMAB FIRST-IN-CLASS ANTI-NKG2A MAB CO-DEVELOPMENT AND COMMERCIALIZATION AGREEMENT WITH ASTRAZENECA
Slide 13: Monalizumab Is a First-in-Class NKG2A Checkpoint Inhibitor
MONALIZUMAB IS A FIRST-IN-CLASS NKG2A CHECKPOINT INHIBITOR SYNERGY WITH PD-(L)1 BLOCKADE AND ADCC ENHANCEMENT NK cell _ Tumor cell Anti-NKG2A NKG2A HLA-E - + Activating Activating + receptor ligand HLA-E MHC PD-L1 NKG2A _ TCR + PD-1 Anti-PD-L1/PD-1 _ + CD8+ T-cell + NK cell and T cell inhibition by
Slide 14: Monalizumab – Joint Clinical Development Plan with AZ-MedImmune
MONALIZUMAB – JOINT CLINICAL DEVELOPMENT PLAN WITH AZ-MEDIMMUNE FOCUS ON COMBINATIONS WITH DURVALUMAB AND CETUXIMAB AZ- Innate Pharma MedImmune Single agent dose ranging study Ovarian CRC NSCLC NSCLC Endometrial SCCHN SCCHN Monalizumab + Monalizumab + Monalizumab + Durvalumab Durvalumab Cetuximab Pa
Slide 15: Monalizumab and Cetuximab Combination in SCCHN
MONALIZUMAB AND CETUXIMAB COMBINATION IN SCCHN Rationale • High level of HLA-E expression in Evaluate safety and define SCCHN MTD/RP2D of mona+cetux • Cetuximab is approved in SCCHN, including in post-platinum setting Assess antitumor activity of • Cetuximab-mediated ADCC is mona+cetux in platinum-
Slide 16: Monalizumab and Cetuximab Phase 2 Study in SCCHN
MONALIZUMAB AND CETUXIMAB PHASE 2 STUDY IN SCCHN KEY FEATURES OF THE PATIENT POPULATION N=31 N=31 Patient Characteristics Previous treatment n (%) n (%) Age, median [range] 64 [34-76] Primary treatment Surgery 18 (58%) Female 10 (32%) Sex Radiation 21 (68%) Male 21 (68%) Systemic therapy 24 (77%) 0
Slide 17: Monalizumab and Cetuximab Combination – Key Clinical Data
MONALIZUMAB AND CETUXIMAB COMBINATION – KEY CLINICAL DATA PRELIMINARY DATA SUGGEST PROMISING ANTI-TUMOR ACTIVITY • Expansion part of ongoing phase 1/2 R/M SCCHN patients trial in advanced SCCHN patients Best Response (N=26), n (%) • Monalizumab (10mg/kg q2w), cetuximab Partial response (PR) 8 (31) (
Slide 18: Anti-Tumor Activity of Monalizumab and Cetuximab
ANTI-TUMOR ACTIVITY OF MONALIZUMAB AND CETUXIMAB % REDUCTION OF TARGET LESION FROM BASELINE1 1 One patient with early death from progression before the 1 st assessment is not represented in these graphs. Cohen et al., AACR 2018 Page 18
Slide 19: Monalizumab and Cetuximab Combination Placed in Context
MONALIZUMAB AND CETUXIMAB COMBINATION PLACED IN CONTEXT CETUXIMAB ALONE IN SECOND LINE SCCHN • Cetuximab alone has limited activity in Med TTP = 70 days platinum pretreated SCCHN • Pivotal phase II study of cetuximab in second line SCCHN (platinum pretreated) • 103 patients Best Response % Med OS =
Slide 20: Monalizumab and Cetuximab Combination Placed in Context
MONALIZUMAB AND CETUXIMAB COMBINATION PLACED IN CONTEXT PD1/PDL1 BLOCKERS ALONE IN SECOND LINE SCCHN Phase 3 study of nivolumab vs standard therapy: med OS = 7.5 months • PD-1/PD-L1 blockers induce a response rate of 13-18% in platinum pretreated SCCHN Best Response % Nivolumab 13% Pembrolizumab 18%
Slide 21: Monalizumab – Ongoing Phase 1 Study, Durvalumab + Monalizumab
MONALIZUMAB – ONGOING PHASE 1 STUDY, DURVALUMAB + MONALIZUMAB Dose-Escalation Mona Mona Mona Mona Mona Dose 1 Q2W Dose 2 Q2W Dose 3 Q2W Dose 4 Q2W Dose 4 Q4W + Durva + Durva + Durva + Durva + Durva N=3 N=3 N=3 N=3 N=3 Dose Expansion MSS CRC Ovarian Endometrial NSCLC N=40 N=36 N=40 N=20 Increasingly
Slide 22: Monalizumab and Durvalumab: Clinical Activity in MSS-CRC Cohort
MONALIZUMAB AND DURVALUMAB CLINICAL ACTIVITY IN MSS-CRC COHORT* MSS-CRC (n=39) Best Overall Response, n (%) CR 0 PR 3 (8%) Thereof unconfirmed CR 1 (3%) SD 11 (28%) PD 22 (56%) NE/NA 3 (8%) Overall response rate, n (%) [95% CI] 3 (8%) [2-22%] Median duration of response, weeks (95% CI) 16.1 (15.9-NE
Slide 23: Monalizumab – Combination Strategy
MONALIZUMAB – COMBINATION STRATEGY LEVERAGE NON REDUNDANT AND SYNERGISTIC PATHWAYS Potentiate responses in IO Unlock responses in IO sensitive tumors resistant tumors SCCHN MSS-CRC Mona + Cetux 3L* Mona + Durva 2-4L Mona + Cetux + SoC 2L Mona + Durva + SoC 1-2L Mona + Cetux + RT/CT LA *3L: Potential
Slide 24: Monalizumab – Commercial Opportunity: SCCHN Current Landscape
MONALIZUMAB – COMMERCIAL OPPORTUNITY IO SOC Other SOC SCCHN – CURRENT COMPETITIVE LANDSCAPE Resectable Unresectable Metastatic 1L 2L 35k* 40k* 65k* 25k* Cis-ineligible Cetuximab + RT 40% Adjuvant CT + Cetuximab IO Mono CT/RT Cis-eligible Cisplatin + RT 60% *Drug-treated patients in US/5EU/Jpn & Chin
Slide 25: Monalizumab – Commercial Opportunity: SCCHN Future Landscape
MONALIZUMAB – COMMERCIAL OPPORTUNITY IO SOC Other SOC SCCHN – FUTURE COMPETITIVE LANDSCAPE Resectable Unresectable Metastatic 1L 2L 3L 35k* 40k* 65k* 25k* 15k* Cis-ineligible Cetuximab + RT Adjuvant Mona + Cetux IO Combo IO Mono CT/RT Cis-eligible IO + RT/CT Mona + Cetux Mona + Cetux *Drug-treated p
Slide 26: IPH4102
IPH4102 FIRST-IN-CLASS ANTI-KIR3DL2 MAB IN-HOUSE DEVELOPMENT
Slide 27: KIR3DL2 Is a Tumor Specific Antigen in CTCL
KIR3DL2 IS A TUMOR SPECIFIC ANTIGEN IN CTCL • IPH4102 is a first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody Page 27
Slide 28: IPH4102 Is a First-in-Class Cytotoxicity-Inducing Antibody
IPH4102 IS A FIRST-IN-CLASS CYTOTOXICITY-INDUCING ANTIBODY DEPLETING KIR3DL2+ T CELL LYMPHOMAS TUMOR CELLS • KIR3DL2 is specifically expressed on cutaneous and circulating cutaneous T-cell lymphomas (CTCL) cells (various grades and subtypes): SS pt, grade IIIB 87% KIR3DL2+ tumor cells1 > Expressed b
Slide 29: IPH4102 – Key Clinical Data
IPH4102 – KEY CLINICAL DATA EMERGING EVIDENCE OF CLINICAL BENEFIT IN DOSE-ESCALATION PART OF PHASE I • Phase I trial in advanced KIR3DL2+ CTCL patients > Repeated and escalating administrations of IPH4102 • 20/25 patients with Sézary syndrome Sézary syndrome patients > Median age – 71 y Best Respons
Slide 30: Encouraging Signs of Clinical Activity
ENCOURAGING SIGNS OF CLINICAL ACTIVITY PATIENTS WITH SÉZARY SYNDROME mDOR: 302 days (9.9 months) Response rate in skin: 60% Min-max (64-519) days Max change (%) in mSWAT score aberrant blood cell count Response rate in blood: 65% mPFS 329 days (10.8 months) Max change (%) in Min-max (28-610) days Be
Slide 31: Significant Pruritus Improvement by VAS Score
SIGNIFICANT PRURITUS IMPROVEMENT BY VAS SCORE VAS: Visual Analogue Scale Bagot et al., EORTC 2017 Page 31
Slide 32: IPH4102 – Targeting T-Cell Lymphoma
IPH4102 – TARGETING T-CELL LYMPHOMA SÉZARY AS THE ENTRY POINT Increasing efficacy Combination Monotherapy Monotherapy ATLL Sézary CTCL PTCL Expanding patient population Page 32
Slide 33: Clinical Development Plan Across Patient Populations
CLINICAL DEVELOPMENT PLAN ACROSS PATIENT POPULATIONS SÉZARY SYNDROME (SS) AS ENTRY POINT Pivotal program IPH4102 in PTCL Pivotal program IPH4102 in ATLL Pivotal program IPH4102 in CTCL Pivotal program IPH4102 in SS 2019 2020 2021 2022 2023 2024 2025 Potential Biologics License Application. All eleme
Slide 34: IPH4102 – Commercial Opportunity
IPH4102 – COMMERCIAL OPPORTUNITY SIGNIFICANT POTENTIAL BEYOND SÉZARY ATLL PTCL Advanced CTCL Sézary 850 pts 15000 pts 3200 pts 1000 pts* • 15% of all NHL • Highly heterogeneous • Medical need in late lines 1L 2L 3L** 3L+ • Differentiated profile • Biomarker driven therapy • Premium pricing strategy
Slide 35: The Tumor Micro-Environment
THE TUMOR MICRO- ENVIRONMENT IPH5401 (ANTI-C5AR) IPH52 (ANTI-CD39) IPH53 (ANTI-CD73)
Slide 36: Mechanism of Action IPH5401
MECHANISM OF ACTION IPH5401 ADDING A C5AR INHIBITOR RESTORES THE EFFICACY OF PD-1/PD-L1 BLOCKERS C5a C5a MHC MHC TCR TCR Anti-PD-1 + Anti-PD-1 or PD-L1 IPH5401 or PD-L1 Combined treatment PD1/PDL1 C5aR receptor blocker + C5aR inh C5aR receptor Ìnhibition of migration & function MDSC/ Neutrophils MDS
Slide 37: C5aR and PD-1 Blockade Delay Tumor Progression
C5AR AND PD-1 BLOCKADE DELAY TUMOR PROGRESSION IPH5401 COULD CREATE A FAVORABLE ENVIRONMENT FOR CHECKPOINT INHIBITORS IC PD-1 • C5a/C5aR blockade works in synergy with anti-PD-1/PD-L1 antibodies in a poorly infiltrated tumor model in vivo > Delay tumor progression and may overcome resistance to anti
Slide 38: IPH5401 – Unlock the Immune Response
IPH5401– UNLOCK THE IMMUNE RESPONSE IN COMBINATION WITH ANTI PD-1/PD-L1 Tumor Incidence * C5aR types expression NSCLC 290K ~80% Reverse IO resistance UCC 50K ~70% Strategy Enhance IO response HCC 110K ~70% CRC 575K 60% Gastric 258K 30-35% Expand into IO refractory tumors TNBC 72K 13-27% Prostate 621
Slide 39: AstraZeneca Collaboration to Accelerate Proof-of-Concept
ASTRAZENECA COLLABORATION TO ACCELERATE PROOF-OF-CONCEPT IN NSCLC AND HCC AstraZeneca/MedImmune Collaboration Type of collaboration Clinical agreement (access to drug, 50% trial cost sharing) Tumor type for expansion NSCLC 2ary resistance (IO pretreated) cohorts = unmet medical needs IO naive HCC PD
Slide 40: IPH52 (Anti-CD39) and IPH53 (Anti-CD73)
IPH52 (ANTI-CD39, FIRST-IN-CLASS) AND IPH53 (ANTI-CD73) TARGETING IMMUNOSUPPRESSIVE TUMOR MICROENVIRONMENT • CD-39 and CD-73 are enzymes expressed on different cells in the TME T Cell Other • Promote immuno-suppression by degrading pro- immune cell inflammatory ATP into immunosuppressive Tumor CD39
Slide 41: Corporate Facts and Figures
CORPORATE FACTS AND FIGURES
Slide 42: Innate Pharma - Financial Highlights
INNATE PHARMA - FINANCIAL HIGHLIGHTS ROBUST FINANCIAL POSITION • Cash, cash equivalents and financial assets* of €153.8m as of March 31, 2018 > Cash consumption 2017: €54m (vs €43m for 2016); including €13.8m milestone payment from BMS > Tax credit for the fiscal year 2016 (€9.1m net) received in Ju
Slide 43: Share Capital
SHARE CAPITAL KEY FIGURES AND ANALYST COVERAGE 15,5% • Listed on Euronext, IPO in November 2006 > Euronext Paris: FR001331421 – IPH 7,6% • Stock liquidity 6,0% > Average daily trading volume >300,000 (YTD) 2,0% > 57.6m outstanding shares (61.1m fully diluted) 68,9% • Analyst coverage: > Bryan Garnie
Slide 44: Investor Relations
INVESTOR RELATIONS investors@innate-pharma.com Dr Markus Metzger Investor Relations markus.metzger@innate-pharma.fr Tel: +33 (0)4 30 30 31 85